Rafael pharmaceuticals partners with sara's cure and sarc for the launch of phase 2 clinical trial for cpi-613® (devimistat) in combination with hydroxychloroquine for patients with clear cell sarcoma of soft tissue

Cranbury, n.j., dec. 01, 2020 (globe newswire) --   rafael pharmaceuticals, inc. (“rafael” or the “company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a phase 2 clinical trial of cpi-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. in partnership with sara's cure and sarcoma alliance for research through collaboration (sarc) , rafael will begin enrolling patients into the simon two-stage design trial at sites across the united states.
RFL Ratings Summary
RFL Quant Ranking